CurvaFix – a developer of medical devices to repair fractures in curved bones – recently announced the close of a $39 million equity financing led by MVM Partners with participation from Sectoral Asset Management and other existing investors. And the company also announced that Mark Foster has been named CEO, succeeding founder and current CEO Steve Dimmer, who will transition into a strategic advisory role.
The $39 million financing proceeds will be used to expand the treatment of Fragility Fractures of the Pelvis (FFP) throughout the U.S. and fundamentally change the course of care for these patients through the nationwide launch of the CurvaFix IM Implant.
Foster is an experienced C-Suite executive with a broad background in the healthcare, medical device, and pharmaceutical industries. And before joining CurvaFix, Foster was president and CEO of Trice Medical, a leader in the field of minimally invasive orthopedic procedures. Formerly he was V.P. of U.S. Sports Medicine Business for Smith and Nephew and also held leadership roles at Boston Scientific.
KEY QUOTE:
“CurvaFix’s ability to benefit patients, physicians, and health systems, while simultaneously addressing the undertreated FFP segment makes CurvaFix a rare asset in the crowded world of orthopedics. We are thrilled to be involved and look forward to supporting the company’s next phase of growth.”
— Eric Fritz, MVM Partner
“I have had the opportunity to observe the successful implementation and adoption of CurvaFix IM Implants in the orthopedic pelvic fracture fixation market, for which Steve has played a pivotal role in taking the company to this point. I am looking forward to leading the CurvaFix team in scaling CurvaFix’s technology to benefit many more patients, physicians, and payers.”
— Mark Foster
“It has been a privilege to lead CurvaFix from concept through commercialization to where it is today, and I am honored to pass off the reins to Mark for this next exciting phase of CurvaFix’s growth.”
— Steve Dimmer
